Business
Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update
Rescheduling aligns with Avicanna’s established pharmaceutical and medical cannabis strate...
About this update from Avicanna Inc
[{"type":"text","content":"Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update\nRescheduling aligns with Avicanna’s established pharmaceutical and medical cannabis strategyRescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, applauds the announcement by the U.S. Department of Justice and U.S. Drug Enforcement Administration to reschedule certain cannabinoid-based products from Schedule I to Schedule III under the U.S. federal Controlled Substances Act, in furtherance of President Trumps Executive Order of December 18, 2025. The Company applauds this development as a meaningful step towards advancing scientific research, improving regulatory clarity, and expanding patient access. The Company is pleased to provide an update of its scientific, R&D, clinical development, and medical affairs initiatives and programs, while continuing to evaluate strategic opportunities in the U.S. Management Commentary “We are encouraged by actions and announcements of the current U.S. Administration toward a more evidence-based and pragmatic framework for cannabinoid-based products” said Aras Azadian, Chief Executive Officer of Avicanna. “This milestone reinforces the importance of rigorous scientific development and aligns closely with Avicanna’s long-standing strategy of advancing pharmaceutical-grade cannabinoid products alongside standardized medical cannabis platforms. As the regulatory landscape evolves, we believe Avicanna is well positioned to leverage its intellectual property portfolio, pipeline, and vertically integrated capabilities to support our strategic roadmap toward participation in the U.S.” Scientific and Medical Highlights (2026 YTD) Clinical Development: Avicanna continues to advance a robust clinical development strategy supported by both real-world evidence and randomized controlled trials. An ongoing real-world evidence study evaluating physician-authorized medical cannabis has published findings demonstrating improvements i...